UPDATE: JP Morgan Raises PT to $39 on Aegerion Pharmaceuticals on Encouraging Juxtapid Sales

JP Morgan maintained Aegerion Pharmaceuticals AEGR with an Overweight rating and raised the price target from $33.00 to $39.00. JP Morgan noted, "AEGR disclosed some encouraging Juxtapid (for HoFH) launch metrics as part of its 4Q update (financials were a non-event). 2013 guidance is unchanged for now (250-300 pts on drug; $15-$25M in net sales), but we suspect it may not stay that way for long. Eighty-five prescriptions were written in just the first 6 weeks of launch. Moreover, management commented that they anticipate steady “orphan like” growth throughout the year. Maintain OW." Aegerion Pharmaceuticals closed at $36.12 on Wednesday.